A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Study Summary

The purpose of this study is to evaluate the long-term safety and efficacy of EDIT-301 in participants with severe sickle cell disease (SCD) or transfusion-dependent β-thalassemia (TDT) who have received EDIT-301.

Conditions

Sickle Cell Disease Transfusion-dependent Beta-Thalassemia Hemoglobinopathies

Interventions / Drugs

Safety and efficacy assessments

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment54 participants

Primary Completion—

Lead SponsorEditas Medicine, Inc.

Data Retrieved2026-04-11 04:12:21.598915+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.